Bayer Thins R&D Pipeline, Backs Finerenone In Kidney But Not Heart Disease

Germany’s leading pharmaceutical company Bayer has taken future competition into account when stopping the Phase III development of finerenone for congestive heart failure, and targeting specific CHF patients for treatment with another potential cardiovascular, vericiguat.